STCube Pharmaceuticals Inc
- Biotech or pharma, therapeutic R&D
STCube Pharmaceuticals, Inc. is a clinical-stage biotech company developing innovative antibody therapies to overcome novel immune evasion mechanisms in cancer. Headquartered in Seoul with research facilities in Maryland, STCube focuses on first-in-class immune checkpoint targets. Its lead candidate, Nelmastobart (hSTC810), is a humanized monoclonal antibody targeting BTN1A1—a newly discovered immune checkpoint predominantly expressed in tumors and distinct from PD-L1. This novel pathway offers therapeutic potential for patients unresponsive to current PD-1/PD-L1 therapies. Following a successful Phase 1 trial, Nelmastobart is now being tested in a Phase 1b/2 trial in metastatic colorectal cancer.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}